TEL AVIV, Israel and MIAMI, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke, today announced that the Marvin Slosman, Chief Executive Officer, will participate in three upcoming investor conferences in November:
Wolfe Research Healthcare Conference
Wednesday, November 15, 2023
Fireside chat: 12:30pm ET
Canaccord Genuity MedTech, Diagnostics, Digital Health & Services Forum
Thursday, November 16, 2023
Investor one-on-one meetings only
Piper 35th Annual Healthcare Conference
Wednesday, November 29, 2023
Fireside chat: 8:00am ET
A live webcast of the presentations will be available in the News and Events section of the Company’s website at www.inspiremd.com/en/events/. Replays will be available on the website for 30 days.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.
We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
This email address is being protected from spambots. You need JavaScript enabled to view it.
Chuck Padala, Managing Director
LifeSci Advisors
646-627-8390
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.61 |
| Daily Change: | -0.02 -0.76 |
| Daily Volume: | 27,218 |
| Market Cap: | US$68.070M |
November 25, 2024 November 12, 2024 September 16, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
